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Ferrara and Brescia, Italy; and Hasselt, BelgiumObjectives This study sought to assess device-speciﬁc outcomes after implantation of bare-metal
stents (BMS), zotarolimus-eluting Endeavor Sprint stents (ZES-S), paclitaxel-eluting stents (PES),
or everolimus-eluting stents (EES) (Medtronic Cardiovascular, Santa Rosa, California) in all-comer
patients undergoing percutaneous coronary intervention.
Background Few studies have directly compared second-generation drug-eluting stents with each
other or with BMS.
Methods We randomized 2,013 patients to BMS, ZES-S, PES, or EES implantation. At 30 days, each stent
group received up to 6 or 24months of clopidogrel therapy. The key efﬁcacy endpointwas the2-yearmajor
adverse cardiac event (MACE) including any death,myocardial infarction, or target vessel revascularization,
whereas the cumulative rate of deﬁnite or probable stent thrombosis (ST) was the key safety endpoint.
Results Clinical follow-up at 2 years was complete for 99.7% of patients. The MACE rate was lowest in
EES (19.2%; 95% conﬁdence interval [CI]: 16.0 to 22.8), highest in BMS (32.1%; 95% CI: 28.1 to 36.3), and
intermediate in PES (26.2%; 95% CI: 22.5 to 30.2) and ZES-S (27.8%; 95% CI: 24.1 to 31.9) groups
(chi-square test¼ 18.9, p¼ 0.00029). The 2-year incidence of ST in the EES group (1%; 95% CI: 0.4 to 2.2)
was similar to that in the ZES-S group (1.4%; 95% CI: 0.7 to 2.8), whereas it was lower compared with the
PES (4.6%, 95% CI: 3.1 to 6.8) and BMS (3.6%; 95% CI: 2.4 to 5.6) groups (chi-square ¼ 16.9; p ¼ 0.0001).
Conclusions Our study shows that cumulative MACE rate, encompassing both safety and efﬁcacy
endpoints, was lowest for EES, highest for BMS, and intermediate for PES and ZES-S groups. EES
outperformed BMS also with respect to the safety endpoints with regard to deﬁnite or probable and
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Abbreviations
and Acronyms
BMS = bare-metal stent(s)
CI = conﬁdence interval
CK-MB = creatine kinase
myocardial band
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PES = paclitaxel-eluting
stent(s)
ST = stent thrombosis
TLR = target lesion
revascularization
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21Randomized, controlled trials (1,2), meta-analyses (3), and
observational studies (4) have consistently shown reduced
rates of angiographic restenosis and ischemia-driven target
vessel revascularization (TVR) with drug-eluting stents
(DES) compared with bare-metal stents (BMS). As a result,
most percutaneous coronary interventions worldwide are
done with DES rather than BMS. However, the higher rates
of very late stent thrombosis (ST) and the concern for a higher
risk of late ST after early discontinuation of dual antiplatelet
agents with ﬁrst-generation DES have raised safety concerns
(5,6). To address these issues, new DES have been developed
with novel materials, designs, and delivery systems, with
improved biocompatible polymers, and new antiproliferative
agents compared with their predecessors. However, most of
these second-generation stents were approved in non-
inferiority trials compared with ﬁrst-generation DES (7–10).
Therefore, few studies have directly compared second-
generation DES with each other or with BMS.
The purpose of this pre-speciﬁed analysis of the
PRODIGY (PROlonging Dual Antiplatelet Treatment
After Grading stent-induced intimal hyperplasia studY) (11)
was to assess device-speciﬁc outcomes in an all-comer patient
population receiving a balanced proportion of ﬁrst- or second-
generation DES or BMS at the time of intervention.
Methods
Study design and population. PRODIGY is a 4  2
randomized, multicenter, open-label clinical trial designed
to evaluate the efﬁcacy and safety of prolonging the duration
of clopidogrel therapy for up to 24 months in all-comer
patients receiving a balanced mixture of stents with varying
anti-intimal hyperplasia potency and belonging to both ﬁrst-
and second-generation DES (11,12).
Patients undergoing elective, urgent, or emergent coro-
nary angioplasty with intended stent implantation at
3 referral Italian sites were randomly assigned in a 1:1:1:1
fashion to 1 of 4 stent types, including everolimus-eluting
stents (EES), paclitaxel-eluting stents (PES), zotarolimus-
eluting Endeavor Sprint stents (ZES-S), or third-generation
thin-strut BMS (Medtronic Cardiovascular, Santa Rosa,
California). At 30 days, patients in each stent group were
randomized in a balanced fashion to either 6 or 24 months
of dual antiplatelet treatment. In the 6-month dual anti-
platelet therapy group, clopidogrel discontinuation at any
time after 30 days was allowed in patients who were
randomized to BMS if coronary intervention was indicated
by the presence of stable coronary artery disease (12).
Individuals eligible for enrollment were patients 18 years of
age or older with chronic stable coronary artery disease or
acute coronary syndromes, including non–ST-segment
elevation myocardial infarction (MI) and ST-segment
elevation MI. They were eligible if they had at least 1 lesion
with a stenosis diameter of 50% that was suitable forcoronary stent implantation in a vessel with a reference vessel
diameter of at least 2.25 mm. Selection criteria were broad,
reﬂecting routine clinical practice. We set no limit for the
number of treated lesions, vessels, or lesion length and
excluded no patients on the basis of comorbid disorders or
age, apart from the following pre-speciﬁed criteria: known
allergy to acetylsalicylic acid or clopidogrel; planned surgery
within 24 months of percutaneous coronary intervention
unless the dual antiplatelet therapy could be maintained
throughout the perisurgical period; history of bleeding
diathesis; major surgery within 15 days; active bleeding
or previous stroke in the past 6 months; concomitant or
foreseeable need for oral anticoagulation therapy; preg-
nancy; life expectancy <24 months; participation in another
trial; and inability to provide informed consent.
The ethics committees of the
3 participating centers indepen-
dently approved the protocol,
and all participants gave written
informed consent.
Treatment protocol and follow-up
procedures. All patients received
aspirin (160 to 325 mg orally or
500 mg intravenously as a loading
dose and then 80 to 160 mg orally
indeﬁnitely) and clopidogrel (300
or 600 mg orally as a loading
dose) and then 75 mg/day for the
treatment duration according to
the randomization scheme as
follows: for either 6 months in the
6-month dual antiplatelet therapy
group in patients randomized to
BMS and presenting with stable
coronary artery disease, a shorter
(but not <30 day) duration of
dual antiplatelet therapy was
allowed to comply with available
evidence or 24 months in the 24-month dual antiplatelet
therapy arm irrespective of the previously implanted stent
type or indication for the coronary procedure.
Anticoagulation during coronary intervention was
accomplished through administration of either unfractio-
nated heparin or bivalirudin. All interventions were per-
formed according to current standard guidelines and the
ﬁnal interventional strategy, including administration of
glycoprotein IIb/IIIa antagonists, pre- or post-dilation, or
the use of intravascular imaging techniques, was left entirely
to the discretion of the operator, except for the stent use.
Angiographic success was deﬁned as residual stenosis <30%
by visual analysis in the presence of Thrombolysis In
Myocardial Infarction ﬂow grade 3.
Follow-up. All randomized patients who were not lost to
follow-up, irrespective of their compliance with the assigned
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22treatment schedule, returned for study visits at 30 days and
then every 6 months up to 2 years. During follow-up visits,
patients were examined, assessed for adverse events, and
underwent 12-lead electrocardiography. Patients lost to
follow-up were censored at the time of the last contact.
Study endpoints. The primary aim of this analysis was to
compare the 2-year outcomes after ﬁrst- or second-generation
DES or BMS with respect to the occurrence of major adverse
cardiac events (MACE), including death of any cause,
nonfatal MI, or TVR. This was a pre-speciﬁed secondary
endpoint of the study, and as no formal sample size assess-
ment was performed. Other secondary objectives included
each component of the primary endpoint, cardiovascular
death, incidence of stent thrombosis deﬁned on the basis
of the Academic Research Consortium criteria (13), and
the incidence of target lesion revascularization (TLR) for the
entire duration of follow-up or from 1 year onward.
Study endpoint deﬁnitions were previously reported (11).
Periprocedural MI in patients without ongoing ischemia
was deﬁned as any increase of >3 times the upper limit
of normal in at least 1 blood sample for creatineFigure 1. Study Proﬁle
2,013 patients were randomized, 10 withdrew consent, 7 were lost to follow-up so tha
metal stent(s); EES ¼ everolimus-eluting stent(s); POBA ¼ plain balloon angioplasty;
stent(s) (Medtronic Cardiovascular, Santa Rosa, California).kinase-myocardial band (CK-MB) fraction in patients with
CK-MB values before the procedure within the normal
range or at least 50% CK-MB elevation after percutaneous
coronary intervention in patients with CK-MB values
higher than the upper limit of normal before the procedure.
Spontaneous MI was based on the detection of increase
and/or decrease in cardiac biomarkers (preferably troponin)
with at least 1 value above the upper limit of normal
together with evidence of myocardial ischemia with at least
1 of the following: symptoms of ischemia; electrocardio-
graphic changes indicative of new ischemia (new ST-T
changes or new left bundle branch block); development of
pathological Q waves on the electrocardiogram.
All study endpoints were conﬁrmed on the basis of docu-
mentation collected at each hospital and were centrally
adjudicated by the clinical events committee, whose members
were unaware of the patients’ treatment-group assignments.
Statistical analysis. Categorical variables were expressed as
frequency (percentage), whereas continuous variables were
expressed as mean  SD. Baseline continuous variables were
compared between randomized groups using analysis oft overall 1,997 patients had complete 2-year follow-up information. BMS ¼ bare-
PES ¼ paclitaxel-eluting stent(s); ZES-S ¼ zotarolimus-eluting Endeavor Sprint









(N ¼ 501) p Value
Age, yrs 69  11 68  11 68  11 68  11 0.47
Male 369 (74) 391 (78) 395 (78) 383 (76) 0.18
Body mass index,
kg/m2
27  4 27  4 27  4 27  4 0.97
Diabetes 118 (24) 118 (24) 140 (28) 120 (24) 0.21
Insulin-dependent 23 (5) 37 (7) 31 (6) 26 (5) 0.64
Hypertension 376 (75) 342 (69) 365 (73) 355 (71) 0.17
Hyperlipidemia 254 (51) 263 (53) 281 (56) 296 (59) 0.09
Current smoking 126 (25) 128 (26) 111 (22) 112 (22) 0.56
Creatinine clearance,
ml/min
76  30 79  33 79  32 80  33 0.46
Previous MI 114 (23) 121 (24) 156 (31) 143 (29) 0.12
Previous CABG 45 (9) 57 (11) 54 (11) 61 (12) 0.29
LVEF 50  11 51  11 50  11 51  10 0.63
Clinical presentation
Stable angina pectoris 122 (24) 137 (27) 154 (31) 125 (25) 0.12
ACS 380 (76) 363 (73) 346 (69) 376 (75) 0.68
Non–ST-segment
elevation ACS
209 (42) 191 (38) 197 (39) 214 (43) 0.66
Unstable angina 93 (19) 92 (18) 83 (17) 99 (20) 0.55
NSTEMI 116 (23) 99 (20) 120 (24) 115 (23) 0.38
STEMI 171 (34) 172 (34) 143 (29) 162 (32) 0.56
Angiographic features 0.21
Single-vessel disease 170 (34) 139 (28) 148 (30) 144 (29)
Multivessel disease 332 (66) 361 (72) 352 (70) 357 (71)
Values are mean  SD or n (%).
ACS ¼ acute coronary syndrome; BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass
graft; EES¼ everolimus-eluting stent(s); LVEF¼ left ventricular ejection fraction; MI¼myocardial
infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PES ¼ paclitaxel-eluting
stent(s); STEMI ¼ ST-segment elevation myocardial infarction; ZES-S ¼ zotarolimus-eluting
Endeavor Sprint stent(s).
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23variance, whereas for baseline binary variables, the likelihood
ratio, chi-square test, or Fisher exact test was used. Post-hoc
comparisons were performed by the Tukey honest signiﬁ-
cance difference test.
Estimation of the cumulative MACE rate was done with
the Kaplan-Meier method, and events were compared by the
log-rank test. To investigate the effect of time on outcome,
the landmark method was also applied, in which the time to
treatment was divided into landmark time intervals (0 to
1 and 1 to 2 years). A 2-sided p value <0.05 was considered
signiﬁcant. All analyses, carried out on the basis of the
intention-to-treat principle, were performed using STATA,
version 11.1 (StataCorp, College Station, Texas).
Results
From December 2006 to December 2008, a total of 2,789
patients underwent screening and 2,013 were ﬁnally
recruited into the study and randomized to receive 1 of the 4
stent types. Ten patients (0.5%) withdrew consent afterintervention, resulting in a ﬁnal patient population of 2,003
patients (Fig. 1).
The 4 stent groups were well balanced with regard to
baseline and angiographic characteristics (Tables 1 and 2),
with the only exception of the circumﬂex artery being more
frequently treated in the PES and EES groups compared
with the other stent groups.
Adherence to aspirin therapy during the course of the
study was high and did not differ across stent groups,
whereas BMS-treated patients received a shorter duration of
clopidogrel therapy. Secondary prevention medications,
including angiotensin-converting enzyme inhibitors, angio-
tensin II receptor blockers, beta-blockers, and statins did not
differ among the 4 stent groups during follow-up (Table 3).
Follow-up and clinical outcomes. Clinical follow-up at 2
years was complete for 99.7% of patients with overall 5 and 2
patients being lost to follow-up after 6 and 12 months,
respectively.
The 2-year cumulative risk of death of any cause, nonfatal
MI or TVR was not homogeneously distributed across the
4 stent types (chi-square ¼ 18.9, p ¼ 0.00029), with
BMS- and EES-treated patients showing the highest
(32.1%) and the lowest (19.2%) event rates, respectively
(Fig. 2). Patients receiving ZES-S (27.8%) or PES (26.2%)
demonstrated intermediate cumulative outcomes. The
12-month landmark analysis failed to show signiﬁcant
heterogeneity across stent types (p ¼ 0.11). Yet, the event
rate remained numerically lower in the EES-treated patients
compared with other stent platforms (Fig. 2).
No clear signal of heterogeneity was noted for the
composite of death or nonfatal MI (Fig. 3) or death alone
across stent groups. The cumulative rate of nonfatal MI rate
also did not differ at 24 months. Yet, the incidence of
nonfatal MI from 12 months onward was higher in the PES
group compared with other stent platforms, even if with
borderline signiﬁcance (p ¼ 0.045).
The cumulative incidence of TVR or TLR alone differed
across stent types and was consistent with the known
potency of each stent to suppress intimal hyperplasia
(Fig. 4). In particular, both TVR and TLR rates were lowest
in the EES group (6.2% and 5.2%, respectively), roughly 3-
fold higher in BMS patients (18.3% and 17.1%, respec-
tively), and intermediate in patients who received PES
(7.8% and 6.8%, respectively) or ZES-S (12.2% and 11.6%,
respectively) (Fig. 4).
The cumulative rate of deﬁnite ST did not signiﬁcantly
differ among the 4 stent groups. On the other hand, the
incidence of deﬁnite or probable ST varied signiﬁcantly across
stent types (chi-square ¼ 16.9, p ¼ 0.0001), being lowest in
EES- (1.0%) and ZES-S– (1.4%) treated patients compared
with the BMS (3.6%) and PES (4.6%) groups (Fig. 5). The
difference in cumulative ST rates across stent groupswas driven
by higher risks of late ST in the BMS and by very late ST in the
PES groups compared with EES- or ZES-S patients.









(N ¼ 501) p Value
No. of treated lesions 1.47  0.8 1.57  1.0 1.58  1.0 1.55  0.9 0.22
2 170 (34) 192 (38) 190 (38) 194 (39) 0.34
3 46 (9) 59 (12) 65 (13) 58 (12) 0.28
4 15 (3) 27 (5) 25 (5) 18 (4) 0.18
Artery treated
LAD 290 (58) 295 (59) 285 (57) 287 (57) 0.76
CFX 147 (29) 149 (30) 163 (33) 186 (37) 0.03
RCA 190 (38) 179 (36) 176 (35) 177 (35) 0.80
SVG treated 9 (2) 13 (3) 12 (2) 13 (3) 0.73
At least 1 complex (type B2 or C) lesion* 318 (63) 343 (69) 339 (68) 315 (63) 0.17
Total ACC/AHA score*y 3.8  2.1 3.9  2.2 3.9  2.3 3.9  2.2 0.38
No. of stents implanted 1.82  1.2 1.91  1.3 1.81  1.3 1.77  1.1 0.34
Length of stent, mm 39  35 41  32 39  29 37  24 0.13
Quantitative coronary analysis
Lesion length, mm 13.07  8.45 13.18  8.32 14.09  9.51 13.13  8.35 0.49
RVD, before, mm 2.64  0.54 2.64  0.51 2.69  0.53 2.63  0.56 0.31
MLD, before, mm 0.60  0.39 0.61  0.38 0.58  0.41 0.59  0.41 0.66
% Stenosis, before 78  14 77  13 79  14 78  16 0.55
RVD, after, mm 2.76  0.50 2.74  0.42 2.86  0.47 2.76  0.50 0.47
MLD, after, mm 2.42  0.56 2.46  0.46 2.53  0.46 2.45  0.49 0.27
% Stenosis, after 10.57  8.25 9.68  8.74 10.01  7.48 11.04  8.67 0.32
Values are mean  SD or n (%). *Calculated in 1,928 patients who presented at least 1 de novo lesion; ACC/AHA score was missing in 3 patients.
yAs previously described (28), type A stenoses were coded 1 point, type B1 stenoses 2 points, type B2 stenoses 3 points, and type C stenoses 4
points. p < 0.05 versus BMS group on post-hoc analysis.
ACC/AHA ¼ American College of Cardiology/American Heart Association; CFX ¼ circumﬂex artery; LAD ¼ left anterior descending artery;
MLD ¼ minimal lumen diameter; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter; SVG ¼ saphenous vein graft; other abbreviations
as in Table 1.
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24These ﬁndings remained consistent when deﬁnite, prob-
able, or possible ST rates were examined.
Discussion
The main ﬁndings of our analysis support the concept that
both efﬁcacy and safety differ considerably across the 4 stent
types used in the present prospective all-comer patient study.
In particular, cumulative MACE rates, encompassing both
safety and efﬁcacy endpoints, were lowest for EES-, highest
for BMS-, and intermediate for PES- and ZES-S–treated
patients.
Although DES are more effective than BMS in reducing
restenosis, their safety has continued to be questioned in
view of the ongoing propensity of ﬁrst-generation DES for
very late ST and the perceived need for prolonged dual
antiplatelet therapy after any DES implantation (5,6).
Moreover, it has been hypothesized that DES safety may be
inversely related to its efﬁcacy (i.e., the higher the stent
potency in late luminal loss inhibition, the more pro-
thrombotic the stent can be) (14). We randomly assigned
patients to receive BMS, ZES-S, PES, or EES, providing,
respectively, no, mild, moderate, or high potency toward
intimal hyperplasia suppression. Moreover, stent platformswere selected for being representative of both ﬁrst- and
second-generation DES technology.
Impact of stent selection on efﬁcacy endpoints. The cumu-
lative rates of TVR or TLR observed at 2-year follow-up
signiﬁcantly differed across the 4 stent types and were
consistent with known potency of each stent platform to
inhibit intimal hyperplasia. In particular, both TVR and
TLR were highest in the BMS and lowest in the EES
groups. Interestingly, a similar pattern was observed for both
stent types at the 1-year landmark analysis, with the BMS
group showing the highest (3.2%), and the EES group
the lowest (1.4%) rates of late TVR. On the other hand,
ZES-S– and PES-treated patients showed heterogeneous
behavior in terms of TVR or TLR throughout follow-up.
ZES-S patients had an incidence of TVR within the ﬁrst
year, which was intermediate between that of the BMS and
EES groups, whereas the late need for reintervention was
low and similar in EES-treated patients. Interestingly, PES
patients showed an opposite TVR pattern over time,
showing among the lowest and highest TVR rates within or
after the ﬁrst year of follow-up, respectively.
Our ﬁndings should be interpreted as conﬁrmatory of
previous observations in terms of both cumulative TVR rates
and distribution pattern of events over time (7,15–20).













No. evaluated 492 493 490 495
Aspirin 492 (100) 493 (100) 490 (100) 495 (100) >0.99
Clopidogrel 491 (100) 247 (99.6) 245 (100) 248 (100) 0.55




415 (84) 419 (84) 421 (84) 417 (84) 0.81
Beta-blockers 397 (81) 419 (85) 409 (83) 414 (84) 0.69
Statins 436 (89) 446 (90) 441 (88) 461 (92) 0.22
At 6 months
No. evaluated 481 485 477 486
Aspirin 476 (99) 481 (99) 472 (99) 484 (100) 0.44
Clopidogrel 333 (69) 480 (99)* 471 (99)* 481 (99)* <0.001




405 (84) 412 (85) 418 (88) 426 (87) 0.41
Beta-blockers 389 (81) 408 (84) 406 (85) 415 (85) 0.29
Statins 423 (88) 438 (90) 429 (90) 387 (93) 0.12
At 12 months
No. evaluated 468 478 464 480
Aspirin 456 (97) 473 (99) 457 (98) 478 (99) 0.22
Clopidogrel 241 (51) 244 (51) 235 (51) 245 (51) 0.89




404 (86) 414 (87) 411 (88) 411 (86) 0.41
Beta-blockers 381 (81) 396 (83) 384 (83) 399 (83) 0.79
Statins 410 (88) 430 (90) 418 (90) 445 (93) 0.22
At 18 months
No. evaluated 465 473 455 472
Aspirin 453 (97) 464 (98) 449 (99) 467 (99) 0.42
Clopidogrel 233 (50) 224 (47) 223 (49) 232 (49) 0.89




393 (85) 400 (85) 394 (87) 411 (87) 0.71
Beta-blockers 365 (78) 382 (81) 369 (81) 382 (81) 0.59
Statins 405 (87) 415 (88) 410 (90) 409 (87) 0.62
At 24 months
No. evaluated 457 465 450 468
Aspirin 444 (97) 454 (98) 440 (98) 463 (99) 0.79
Clopidogrel 226 (49) 214 (46) 217 (48) 228 (49) 0.89




349 (76) 369 (79) 368 (82) 365 (78) 0.21
Beta-blockers 355 (78) 345 (74) 328 (73) 345 (74) 0.49
Statins 364 (80) 374 (80) 350 (83) 387 (86) 0.12
Values are n (%). *p < 0.05 versus BMS group on post-hoc analysis.
ACE ¼ angiotensin-converting enzyme; other abbreviations as in Table 1.
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25Impact of stent selection on safety endpoints. The com-
posite of death or nonfatal MI did not formally differ across
stent types. Consistent ﬁndings were noted for cumulative
death of any cause and MI rates, separately analyzed.
Yet, MI rates at the 1-year landmark analysis were not
homogeneously distributed across the 4 stent types, with
a roughly 2-fold increase of events in patients treated with
PES (4.8%) compared with EES (2.4%). ST rates were also
not homogeneously distributed across stent types, both with
respect to the cumulative incidence or distribution of events
over time. EES-treated patients showed the lowest cumu-
lative rate of ST at 2 years, which was the result of
a consistently low incidence of acute/subacute, late, and very
late ST. Similar ﬁndings were noted for the ZES-S group.
On the other hand, the PES and BMS groups had the
highest risk of cumulative ST, which was driven by a high
incidence of late ST rates in the BMS and very late (>1
year) ST in the PES groups.
Intimal hyperplasia is known to peak at 11 to 14 weeks
after BMS implantation and then it stabilizes or even mildly
regresses (the so-called compaction phenomenon) over time
(21). Therefore, it remains possible that the high rate of late
ST in the BMS group may reﬂect symptomatic late loss–
driven occlusive or subocclusive restenosis. The possible
contribution of late luminal loss to late ST was postulated in
several previous head-to-head trials or registry data
(15,22,23), and it has major clinical implications, as it would
question the concept that stent safety inversely relates to
stent potency in inhibiting intimal hyperplasia. Alterna-
tively, some DES polymers may increase the biocompati-
bility of the BMS surface and as such render the stent itself
less thrombogenic (24).
The relatively higher risk of very late ST with PES
compared with the second-generation DES tested in the
current study is not new and is consistent with many previous
observations (9,20). This ﬁnding reinforces the concept
that DES safety is highly heterogeneous across DES types.
In particular, we even observed an improved safety proﬁle
for EES, with respect to deﬁnite or probable ST, com-
pared with BMS. In this regard, the EXAMINATION
(Evaluation of the Xience-V stent in Acute Myocardial
INfArcTION) trial was the ﬁrst reasonably sized study of
second-generation DES and BMS and reported signiﬁcantly
lower rates of ST with EES than with BMS at 1-year follow-
up (25). A recent network meta-analysis involving 49
randomized studies, of which only 2 directly comparing EES
with BMS corroborated this possible paradigm shift (26).
Therefore, our data, although preliminary, suggest that
stent safety may not be necessarily disconnected from efﬁcacy,
which has major clinical and pathophysiological implications.
Study limitations. First, the open-label design may have
introduced the potential for bias. We minimized this
potential with the requirement that all events were adjudi-
cated by independent committees unaware of the treatment
Figure 2. Cumulative Incidence of the Key Efﬁcacy Endpoint According to Stent Group
Cumulative incidence curves are shown for the key efﬁcacy endpoints of death of any cause, myocardial infarction (MI), or target vessel revascularization (TVR) at 2-year
follow-up and from 1-year landmark analysis. The p values were calculated using the log-rank test. Other abbreviations as in Figure 1.
Valgimigli et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 1 , 2 0 1 4
Stent Comparative Effectiveness J A N U A R Y 2 0 1 4 : 2 0 – 8
26assignments. Our study was not powered for the comparison
of the 4 stent platforms. As such, our ﬁndings are explor-
atory and hypothesis generating and deserve further
conﬁrmation.
This is particularly true considering that the analyses of
multiple safety and efﬁcacy endpoints at 2 years or from the
landmark of 1-year follow-up for the 4 randomized stentFigure 3. Cumulative Incidence of Death or Nonfatal MI According to Stent Grou
Cumulative incidence curves are shown for death of any cause or myocardial infarctio
calculated using the log-rank test. Abbreviations as in Figure 1.groups made possible multiple comparisons, for which
a formal level of signiﬁcance was not corrected.
The focus of the current analysis was to contrast the
performance of the 4 different stent types. Hence, we did
not speciﬁcally investigate the possible stent type by clopi-
dogrel duration interaction because this information was
previously reported (27).p
n (MI) at 2-year follow-up and from 1-year landmark analysis. The p values were
Figure 4. Cumulative Incidence of TVR According to Stent Group
Cumulative incidence curves are shown for the death for TVR at 2-year follow-up and from 1-year landmark analysis. The p values were calculated using the log-rank
test. Abbreviations as in Figure 2.
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27Conclusions
Our study suggests that the unrestricted EES implantation in
a broad consecutive patient population is associated with the
lowest MACE risk across the 4 randomized stent platforms.
The superiority of EES was driven by a better efﬁcacy proﬁle
in terms of TVR rates compared with both BMS or ZES-SFigure 5. Cumulative Incidence of the Key Safety Endpoint According to Stent G
Cumulative incidence curves are shown for the key safety endpoint of deﬁnite or pr
using the log-rank test. Abbreviations as in Figure 1.but importantly also by an improved safety proﬁle with
respect to ST rates compared with PES or BMS. Finally,
PES and ZES-S were associated with MACE rates, which
were intermediate between EES and BMS, as a result of
a suboptimal safety and efﬁcacy proﬁle, respectively.
The observation that EES implantation is associated with
a lower ST rate compared with BMS is consistent withroup
obable stent thrombosis (ST) at 2-year follow-up. The p values were calculated
Valgimigli et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 1 , 2 0 1 4
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28a paradigm shift, which has major potential clinical impli-
cations and should be conﬁrmed by appropriately powered
clinical investigations.Reprint requests and correspondence: Dr. Marco Valgimigli,
Thoraxcenter, Ba 587, Erasmus MC, Rotterdam, the Netherlands.
E-mail: m.valgimigli@erasmusmc.nl.REFERENCES
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